MX2024004214A - Combinaciones de inhibidores de kras g12d con irinotecán y métodos de tratamiento relacionados. - Google Patents

Combinaciones de inhibidores de kras g12d con irinotecán y métodos de tratamiento relacionados.

Info

Publication number
MX2024004214A
MX2024004214A MX2024004214A MX2024004214A MX2024004214A MX 2024004214 A MX2024004214 A MX 2024004214A MX 2024004214 A MX2024004214 A MX 2024004214A MX 2024004214 A MX2024004214 A MX 2024004214A MX 2024004214 A MX2024004214 A MX 2024004214A
Authority
MX
Mexico
Prior art keywords
kras
irinotecan
inhibitors
combinations
treatment
Prior art date
Application number
MX2024004214A
Other languages
English (en)
Spanish (es)
Inventor
James Gail Christensen
Peter Olson
Jill Hallin
Vickie Bowcut
Original Assignee
Mirati Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics Inc filed Critical Mirati Therapeutics Inc
Publication of MX2024004214A publication Critical patent/MX2024004214A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2024004214A 2021-10-05 2022-10-04 Combinaciones de inhibidores de kras g12d con irinotecán y métodos de tratamiento relacionados. MX2024004214A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163252405P 2021-10-05 2021-10-05
PCT/US2022/045625 WO2023059600A1 (en) 2021-10-05 2022-10-04 Combinations of kras g12d inhibitors with irinotecan and related methods of treatment

Publications (1)

Publication Number Publication Date
MX2024004214A true MX2024004214A (es) 2024-07-29

Family

ID=85803676

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024004214A MX2024004214A (es) 2021-10-05 2022-10-04 Combinaciones de inhibidores de kras g12d con irinotecán y métodos de tratamiento relacionados.

Country Status (10)

Country Link
US (1) US20250249003A1 (cg-RX-API-DMAC7.html)
EP (1) EP4412720A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024537137A (cg-RX-API-DMAC7.html)
KR (1) KR20240073115A (cg-RX-API-DMAC7.html)
CN (1) CN118354794A (cg-RX-API-DMAC7.html)
AU (1) AU2022361219A1 (cg-RX-API-DMAC7.html)
CA (1) CA3233571A1 (cg-RX-API-DMAC7.html)
IL (1) IL311863A (cg-RX-API-DMAC7.html)
MX (1) MX2024004214A (cg-RX-API-DMAC7.html)
WO (1) WO2023059600A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250114346A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
KR20260110993A (ko) 2023-10-09 2026-07-14 인사이트 코포레이션 Kras g12d 억제제 및 egfr 억제제를 포함하는 암 치료용 조합
CN122459678A (zh) 2023-12-29 2026-07-24 百时美施贵宝公司 KRAS抑制剂与Treg耗竭剂的组合疗法
US20260137674A1 (en) 2024-10-23 2026-05-21 Incyte Corporation Combination therapy using a kras g12d inhibitor, and a nucleoside analog, and/or a microtubule inhibitor
WO2026090333A1 (en) 2024-10-23 2026-04-30 Incyte Corporation Combination using a kras g12d inhibitor and chemotherapy combinations as well as their use in the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
WO2017172678A1 (en) 2016-03-30 2017-10-05 Merrimack Pharmaceuticals, Inc. Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
WO2021106231A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation

Also Published As

Publication number Publication date
JP2024537137A (ja) 2024-10-10
IL311863A (en) 2024-06-01
EP4412720A4 (en) 2025-08-13
WO2023059600A1 (en) 2023-04-13
CA3233571A1 (en) 2023-04-13
CN118354794A (zh) 2024-07-16
KR20240073115A (ko) 2024-05-24
EP4412720A1 (en) 2024-08-14
US20250249003A1 (en) 2025-08-07
AU2022361219A1 (en) 2024-04-11

Similar Documents

Publication Publication Date Title
MX2024004215A (es) Terapias combinadas de inhibidores de kras g12d con inhibidores de sos1.
MX2024004213A (es) Combinaciones de inhibidores de kras g12d con inhibidores de pi3ka y métodos de tratamiento relacionados.
MX2024009727A (es) Terapias de combinacion.
MX2024012131A (es) Composicion farmaceutica, uso de la misma y metodo para tratar el cancer
MX2023015236A (es) Combinaciones farmaceuticas que comprenden un inhibidor de kras g12c y sus usos para el tratamiento de cancer.
EP4552631A3 (en) Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer
ZA202300875B (en) Kat6 inhibitor methods and combinations for cancer treatment
MX2024004444A (es) Compuestos de quinolina como inhibidores de la proteina del virus de sarcoma de rata kirsten (kras).
EA202190749A1 (ru) Способы комбинированной терапии
PH12021552675A1 (en) Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
MX387885B (es) Inhibidores de ezh2 para tratar linfomas.
MX2024003922A (es) Inhibidores de parp1 de azetidina y pirrolidina y usos de estos.
MX2021008610A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
MX2020011684A (es) Inhibicion combinada de pd-1/pd-l1, tgfbeta y dna-pk para el tratamiento del cancer.
MX2025008920A (es) Inhibidores de parp1 triciclicos y usos de estos
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
AU2010266004A8 (en) Method of treating cancer with Dll4 antagonist and chemotherapeutic agent
PH12022553501A1 (en) Alk2 inhibitors for the treatment of anemia
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
MX2025001990A (es) Agente terapeutico y metodo terapeutico que son para pacientes con cancer que presentan deterioro funcional de la proteina del retinoblastoma (rb1) y que implican el uso concomitante de inhibidor del factor de transcripcion 1 de mielina (myt1) y agente quimioterapeutico
MX2024006678A (es) Inhibidor de cdk4 para el tratamiento del cancer.
MX2025007378A (es) Inhibidores de ctps1 para usarse en el tratamiento de cancer deficiente de ctps2
WO2023196086A3 (en) Combination therapies comprising a sos1 inhibitor and an egfr inhibitor